{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T04:06:41Z","timestamp":1741925201991,"version":"3.38.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271374"],"award-info":[{"award-number":["82271374"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["JQ23027"],"award-info":[{"award-number":["JQ23027"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.msard.2025.106313","type":"journal-article","created":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T15:10:00Z","timestamp":1738509000000},"page":"106313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cerebrospinal fluid interleukin-6 may be a biomarker for conversion of clinically isolated syndrome to neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4701-5157","authenticated-orcid":false,"given":"Yuzhen","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huabing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Decai","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiali","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lulin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinghu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106313_bib0033","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/cei.12733","article-title":"Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase","volume":"183","author":"Barros","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2025.106313_bib0028","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.msard.2025.106313_bib0011","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cca.2014.11.004","article-title":"Biomarkers for neuromyelitis optica","volume":"440","author":"Chang","year":"2015","journal-title":"Clin. Chim. Acta; Int. J. Clin. Chem."},{"key":"10.1016\/j.msard.2025.106313_bib0030","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.msard.2025.106313_bib0026","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.it.2007.01.005","article-title":"Astrocytes are active players in cerebral innate immunity","volume":"28","author":"Farina","year":"2007","journal-title":"Trends Immunol."},{"key":"10.1016\/j.msard.2025.106313_bib0018","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/brain\/awm329","article-title":"Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis","volume":"131","author":"Fisniku","year":"2008","journal-title":"Brain: J. Neurol."},{"key":"10.1016\/j.msard.2025.106313_bib0022","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106313_bib0014","doi-asserted-by":"crossref","DOI":"10.2169\/internalmedicine.8709-21","article-title":"SARS-CoV-2-related myelin oligodendrocyte glycoprotein antibody-associated disease: a case report and literature review","author":"Ide","year":"2022","journal-title":"Int. Med."},{"key":"10.1016\/j.msard.2025.106313_bib0005","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain: J Neurol."},{"key":"10.1016\/j.msard.2025.106313_bib0038","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106313_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.immunol.23.021704.115806","article-title":"Interleukin-6: from basic science to medicine\u201340 years in immunology","volume":"23","author":"Kishimoto","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.msard.2025.106313_bib0009","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2025.106313_bib0024","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 Cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.msard.2025.106313_bib0021","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/1352458514568827","article-title":"Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study","volume":"21","author":"Kuhle","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106313_bib0004","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2025.106313_bib0003","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2025.106313_bib0037","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"Lopez-Chiriboga","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106313_bib0016","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2025.106313_bib0019","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1212\/WNL.0000000000000830","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"83","author":"Mao","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106313_bib0042","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1212\/WNL.0b013e318296e917","article-title":"Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity","volume":"80","author":"Marignier","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106313_bib0015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106313_bib0012","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1212\/NXI.0000000000000134","article-title":"Update on biomarkers in neuromyelitis optica","volume":"2","author":"Melamed","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106313_bib0002","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(11)70274-5","article-title":"Clinically isolated syndromes","volume":"11","author":"Miller","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106313_bib0008","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106313_bib0025","doi-asserted-by":"crossref","first-page":"14292","DOI":"10.1073\/pnas.1009234107","article-title":"Proinflammatory T helper type 17 cells are effective B-cell helpers","volume":"107","author":"Mitsdoerffer","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.msard.2025.106313_bib0020","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458514564482","article-title":"Subclinical central inflammation is risk for RIS and CIS conversion to MS","volume":"21","author":"Rossi","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106313_bib0017","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1212\/WNL.0b013e318296ea08","article-title":"Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders","volume":"80","author":"Sato","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106313_bib0001","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/brain\/awq118","article-title":"The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability","volume":"133","author":"Scalfari","year":"2010","journal-title":"Brain: J. Neurol."},{"key":"10.1016\/j.msard.2025.106313_bib0040","first-page":"1","article-title":"The pharmacological management of myelin oligodendrocyte glycoprotein-immunoglobulin G associated disease (MOGAD): an update of the literature","author":"Schiro","year":"2024","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.msard.2025.106313_bib0036","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.drudis.2021.03.018","article-title":"Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: implications from immunology, the FcRn pathway and clinical experience","volume":"26","author":"Sellner","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.msard.2025.106313_bib0023","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.msard.2025.106313_bib0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2015.02.012","article-title":"Analysis of the treatment of neuromyelitis optica","volume":"351","author":"Torres","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106313_bib0039","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106313_bib0032","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1177\/1352458516672015","article-title":"Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: their possible role on blood-brain barrier disruption","volume":"23","author":"Uchida","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106313_bib0010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1468-1331.2009.02897.x","article-title":"Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis","volume":"17","author":"Uzawa","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106313_bib0031","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106313_bib0027","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bpa.12097","article-title":"Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications","volume":"24","author":"Uzawa","year":"2014","journal-title":"Brain Pathol."},{"key":"10.1016\/j.msard.2025.106313_bib0034","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cca.2017.03.006","article-title":"Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: a special focus on neuromyelitis optica","volume":"469","author":"Uzawa","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.msard.2025.106313_bib0041","first-page":"99","article-title":"Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays","volume":"15","author":"Waters","year":"2008","journal-title":"Int. MS J."},{"key":"10.1016\/j.msard.2025.106313_bib0013","first-page":"1","article-title":"Cytokines and tissue damage biomarkers in first-onset neuromyelitis optica spectrum disorders: significance of interleukin-6","author":"Wei","year":"2018","journal-title":"NeuroImmunoModulation"},{"key":"10.1016\/j.msard.2025.106313_bib0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000494976","article-title":"Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: significance of Interleukin-6","volume":"25","author":"Wei","year":"2018","journal-title":"NeuroImmunoModulation"},{"key":"10.1016\/j.msard.2025.106313_bib0006","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1185\/03007995.2013.787979","article-title":"Consensus guidelines for the diagnosis and treatment of multiple sclerosis","volume":"29","author":"Yamout","year":"2013","journal-title":"Curr. Med. Res. Opin."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T04:48:46Z","timestamp":1741841326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":42,"alternative-id":["S2211034825000574"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106313","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cerebrospinal fluid interleukin-6 may be a biomarker for conversion of clinically isolated syndrome to neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106313","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106313"}}